Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 1 September 2017

Zealand increases its share capital as a consequence of exercise of employee warrants

Zealand Pharma    

Published: 09:18 CEST 01-09-2017 /GlobeNewswire /Source: Zealand Pharma / : ZEAL /ISIN: DK0060257814

Zealand increases its share capital as a consequence of exercise of employee warrants

Company announcement - No. 43 / 2017

 

Zealand increases its share capital as a consequence of exercise of employee warrants

 

Copenhagen, September 1, 2017 - Zealand has increased its share capital by a nominal amount of DKK 1,500 divided into 1,500 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre specified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand's warrant programs, see the company's Articles of Association, which are available on the website: www.zealandpharma.com.

 

The exercise price was DKK 87.45 per share and the total proceeds to Zealand from the capital increase amount to DKK 131,175.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand has only one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 30,720,152 divided into 30,720,152 shares with a nominal value of DKK 1 each.

The amendment to Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel.: +45 51 67 61 28, e-mail:
bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

 

 

About Zealand Pharma A/S

Zealand (Nasdaq Copenhagen and New York: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines.

Zealand is based in Copenhagen (Glostrup), Denmark.

 



43 -17_0901_announcement_capital increase



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Zealand Pharma, Smedeland 36, Glostrup 2600, Danmark
If you would like to unsubscribe and stop receiving these e-mails click here.